This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

Shares of Adeza Biomedical (ADZA) were among health care stocks' winners Monday, rising more than 50% on news of a merger.

Cytyc (CYTC) agreed to acquire the maker of products for women's health for $24 a share, or $452 million. The merger is expected to close by the end of March. Shares of Adeza were up $8.25, or 53%, to $23.78 in recent trading. Cytyc shares were up 59 cents, or 2%, at $30.14.

Onyx Pharmaceuticals (ONXX) was surging 91% Monday after the company said a trial of the liver cancer drug Nexavar met its primary endpoint . Onyx and partner Bayer (BAY) ended the phase III trial early on recommendation of an independent data-monitoring committee and gave all patients in the study access to Nexavar. Onyx shares were up $11.14 at $23.40 in recent trading.

Bristol-Myers Squibb (BMY - Get Report) dropped lower on reports that merger talks with Sanofi-Aventis (SNY) have come to an end. Bristol shares were recently down $1.05, or 3.7%, at $27.47, while Sanofi was higher by 24 cents, or 0.6%, at $44.02.

Medifast (MED - Get Report) climbed higher on an 83% year-over-year increase in full-year revenue. The weight-loss company reported unaudited revenue of $73.5 million, up from $40.1 million in 2005 and higher than its previous guidance of $70 million to $72 million. Analysts are looking for $73.3 million in revenue, according to Thomson First Call. Shares were recently higher by $1.37, or 17.6%, at $9.14.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
BMY $67.85 -0.34%
MED $31.84 -0.09%
LCAV $5.37 0.00%
AAPL $117.81 -0.19%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs